How to monitor impurities and ensure consistent gene therapies
- with only one easily accessible assay
One of the biggest challenges in developing advanced therapy medicinal products and viral vaccines is ensuring and documenting that the downstream process consistently produces a safe product.
Neither ELISA, SDS PAGE, nor Western blotting can sufficiently identify and quantify process-related impurities in the complex products. And what’s more, these traditional methods offer only minimal monitoring of individual protein impurities.
Do you know the new solution (LC-MS) that more and more CGT companies turn to?
In this webinar, you will learn how to quickly identify and quantify all proteins using only one assay – irrespective of the source of the proteins.YES, sign me up >>